Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst | 11 | Benzinga.com | ||
Mo | Silence Therapeutics plc: Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting | 308 | Business Wire | New zerlasiran data show significant time-averaged Lp(a) reductions with effects persisting 60 weeks following the first dose Represents first study to report time-averaged Lp(a) results to further... ► Artikel lesen | |
Fr | Analyst Scoreboard: 4 Ratings For Silence Therapeutics | 2 | Benzinga.com | ||
14.11. | Silence Therapeutics reports Q3 results | 2 | Seeking Alpha | ||
14.11. | Silence Therapeutics plc - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
14.11. | Silence Therapeutics plc: Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | 261 | Business Wire | Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered... ► Artikel lesen | |
14.11. | Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | 75 | Business Wire | LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical stage biotechnology company committed to transforming people's lives by silencing... ► Artikel lesen | |
13.11. | Silence Therapeutics plc: Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference | 149 | Business Wire | Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered... ► Artikel lesen | |
SILENCE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
08.10. | Morgan Stanley Reaffirms Overweight Rating for Silence Therapeutics (NASDAQ:SLN) | 12 | MarketBeat | ||
02.09. | Silence Therapeutics shares start at Buy from Jefferies, reflecting strong clinical data | 4 | Investing.com | ||
30.08. | H.C. Wainwright reiterates Buy on Silence Therapeutics stock amid strong trial results | 1 | Investing.com | ||
27.08. | Silence Therapeutics plc: Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences | 200 | Business Wire | Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision... ► Artikel lesen | |
16.08. | Silence Therapeutics stock holds top pick spot and outperform rating at BMO | 1 | Investing.com | ||
16.08. | Analyst Expectations For Silence Therapeutics' Future | 2 | Benzinga.com | ||
16.08. | Silence Therapeutics reports Q2 results | 2 | Seeking Alpha | ||
15.08. | Silence Therapeutics plc - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
15.08. | Silence Therapeutics plc: Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights | 607 | Business Wire | Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision... ► Artikel lesen | |
15.08. | Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights | 163 | Business Wire | LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing... ► Artikel lesen | |
27.06. | Silence Therapeutics plc - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
24.06. | Silence Therapeutics Receives $2M Milestone Payment from Hansoh | 3 | Contract Pharma |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PFIZER | 23,890 | +0,93 % | UBS stuft PFIZER INC auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Pfizer nach einer UBS-Konferenz auf "Neutral" mit einem Kursziel von 31 US-Dollar belassen. Nach einem bisher durchwachsenen... ► Artikel lesen | |
NOVO NORDISK | 98,02 | -1,98 % | Novo Nordisk, BioNxt Solutions, Bavarian Nordic - Chancen nach der Horror-Woche | Die abgelaufene Börsenwoche war eine zum Vergessen für den Biotech- und Medtechsektor. Durch die Nominierung des impfkritischen Robert F. Kennedy als zukünftigen US-Gesundheitsministers verloren Aktien... ► Artikel lesen | |
MERCK KGAA | 138,30 | +0,14 % | Merck Aktie: Was kommt? | ||
ELI LILLY | 715,90 | +0,27 % | Eli Lilly: Ein schwarzer Tag für Pharma- und Biotech-Aktien | Der designierte US-Gesundheitsminister Robert F. Kennedy Jr. sorgte zum Ende der vorigen Woche für Turbulenzen in der Welt der Pharma- und Biotechwerte Den vollständigen Artikel lesen ... ► Artikel lesen | |
VERTEX PHARMACEUTICALS | 429,85 | +0,40 % | VERTEX - Wie kurz sind die Beine politischer Börsen? | ||
INNOCAN PHARMA | 0,156 | +11,87 % | Breaking News: InnoCan Pharma erzielt 24 Mio. USD Umsatz… | ||
VIATRIS | 12,660 | +1,56 % | Viatris fined in Morocco over merger notification, sources say | ||
SCHOTT PHARMA | 26,220 | -0,38 % | EQS-AFR: SCHOTT Pharma AG & Co. KGaA: Vorabbekanntmachung über die Veröffentlichung von Quartalsberichten und Quartals-/Zwischenmitteilungen | EQS Vorabbekanntmachung Finanzberichte: SCHOTT Pharma AG & Co. KGaA
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
SCHOTT Pharma AG & Co. KGaA:... ► Artikel lesen | |
IONIS PHARMACEUTICALS | 32,000 | -4,71 % | Ionis Pharmaceuticals (NASDAQ:IONS) Hits New 12-Month Low on Insider Selling | ||
ALNYLAM PHARMACEUTICALS | 237,00 | +0,38 % | Alnylam Presents New Phase 1 Results For Next-Gen RNAi Therapy Nucresiran In ATTR Amyloidosis | WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals Inc. (ALNY) has shared new findings from its Phase 1 study of nucresiran (previously known as ALN-TTRsc04), a next-generation RNAi therapy being... ► Artikel lesen | |
CASSAVA SCIENCES | 31,900 | +28,99 % | Cassava Sciences, Inc.: Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer | ||
ALTIMMUNE | 8,257 | +8,16 % | Altimmune, Inc: Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting 2024 | ||
MEDPACE | 322,70 | +4,26 % | Medpace Holdings, Inc. Reports Third Quarter 2024 Results | CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the third quarter ended September 30, 2024.
Third Quarter 2024 Financial Results
Revenue... ► Artikel lesen | |
ROCKET LAB USA | 21,150 | +10,50 % | Is Rocket Lab Stock a Millionaire Maker? | ||
DAIICHI SANKYO | 28,180 | +2,14 % | EQS-News: Daiichi Sankyo Deutschland GmbH: Die Investitionen von Daiichi Sankyo in Krebsmedikamente nehmen Gestalt an: Zum Baubeginn des Produktionsgebäudes besucht Ministerpräsident Söder das Werk in Pfaffenhofen | Emittent / Herausgeber: Daiichi Sankyo Deutschland GmbH
/ Schlagwort(e): Expansion
Die Investitionen von Daiichi Sankyo in Krebsmedikamente nehmen Gestalt an: Zum Baubeginn des... ► Artikel lesen |